Lung Cancer Clinical Trial
Official title:
Functional Outcomes for Stereotactic Body Radiotherapy of Lung Lesions in High Risk Patients
Little is known about the safety of body radiation therapy (SBRT), especially the impact on
pulmonary function, quality of life, and on functional changes within the lung itself.
Radiation dose constraints and capturing functional changes on imaging are not well studied
in this setting.
The current study aims to evaluate the utility of advanced imaging to measure lung function
prior to and after treatment and to assess the feasibility of using this data to adapt SBRT
planning.
Stereotactic body radiation therapy (SBRT) is becoming a new standard for unresectable lung
metastases and primary lung cancers.
However, it is becoming increasingly common for patients to undergo multiple courses of lung
SBRT to synchronous and/or metachronous lung lesions. Further, the indications for SBRT are
being expanded to patients who have very poor pulmonary function such as FEV1 < 0.5 L or DLCO
< 35% predicted, who have large tumors (>3 cm), or who have centrally located lesions that
abut great vessels and mainstem bronchi. Little is known about the safety of such treatments,
especially the impact on pulmonary function, quality of life, and on functional changes
within the lung itself. Radiation dose constraints and capturing functional changes on
imaging are not well studied in this setting.
The current study aims to evaluate the utility of advanced imaging to measure lung function
prior to and after treatment and to assess the feasibility of using this data to adapt SBRT
planning. SPECT/CT will be used to measure ventilation and perfusion changes while. CT
ventilation scans will be used to correlate functional changes observed on diagnostic
SPECT/CT. Dynamic contrast enhanced MRI (DCE-MRI) will also be used to explore local vascular
changes in the treated tumor. In patients whose tumors lie close to the heart, cardiac MRI
will be used to investigate whether high doses of radiation per fraction are associated with
changes in cardiac function. These imaging modalities may be used to potentially predict
toxicity and patient response with the ultimate goal of prospectively adapt dose to
individual patient and tumor characteristics. Lung function prior to and post-treatment will
also be measured as a correlate of functional imaging changes. Identifying areas of the lung
that are sub-functional or low-functioning may offer an opportunity to adapt stereotactic
ablations that spare functional lung thereby making SBRT treatments to higher risk patients
safer.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03918538 -
A Series of Study in Testing Efficacy of Pulmonary Rehabilitation Interventions in Lung Cancer Survivors
|
N/A | |
Recruiting |
NCT05078918 -
Comprehensive Care Program for Their Return to Normal Life Among Lung Cancer Survivors
|
N/A | |
Active, not recruiting |
NCT04548830 -
Safety of Lung Cryobiopsy in People With Cancer
|
Phase 2 | |
Completed |
NCT04633850 -
Implementation of Adjuvants in Intercostal Nerve Blockades for Thoracoscopic Surgery in Pulmonary Cancer Patients
|
||
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT05583916 -
Same Day Discharge for Video-Assisted Thoracoscopic Surgery (VATS) Lung Surgery
|
N/A | |
Completed |
NCT00341939 -
Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
|
||
Not yet recruiting |
NCT06376253 -
A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers
|
Phase 1 | |
Recruiting |
NCT05898594 -
Lung Cancer Screening in High-risk Black Women
|
N/A | |
Active, not recruiting |
NCT05060432 -
Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03667716 -
COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.
|
Phase 1 | |
Active, not recruiting |
NCT03575793 -
A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer
|
Phase 1/Phase 2 | |
Terminated |
NCT01624090 -
Mithramycin for Lung, Esophagus, and Other Chest Cancers
|
Phase 2 | |
Terminated |
NCT03275688 -
NanoSpectrometer Biomarker Discovery and Confirmation Study
|
||
Not yet recruiting |
NCT04931420 -
Study Comparing Standard of Care Chemotherapy With/ Without Sequential Cytoreductive Surgery for Patients With Metastatic Foregut Cancer and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid Levels
|
Phase 2 | |
Recruiting |
NCT06052449 -
Assessing Social Determinants of Health to Increase Cancer Screening
|
N/A | |
Recruiting |
NCT06010862 -
Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors
|
Phase 1 | |
Not yet recruiting |
NCT06017271 -
Predictive Value of Epicardial Adipose Tissue for Pulmonary Embolism and Death in Patients With Lung Cancer
|
||
Recruiting |
NCT05787522 -
Efficacy and Safety of AI-assisted Radiotherapy Contouring Software for Thoracic Organs at Risk
|